Skip to main content
Premium Trial:

Request an Annual Quote

Epitome Biosystems, EMD Biosciences to Develop Tools Based on Epitome EpiTag Tech

NEW YORK, Sept. 16 (GenomeWeb News) - Epitome Biosystems and EMD Biosciences have signed a licensing and development agreement to develop products based on Epitome's EpiTag technology, the companies announced this week.


According to terms of the agreement, Epitome will develop reagents for the quantitative measurement of key interacellular signaling proteins. Products will be marketed and sold worldwide by EMD Biosciences under its Novagen and Calbiochem brands.


Epitome will receive a technology access fee, milestone-based development payments, and royalties on product sales.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.